Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by mollevi
Group name PlateformeIPAM
Item Type Journal Article
Title Pharmacological inhibition of Dock5 prevents osteolysis by affecting osteoclast podosome organization while preserving bone formation
Creator Vives et al.
Author Virginie Vives
Author Gaëlle Cres
Author Christian Richard
Author Muriel Busson
Author Yann Ferrandez
Author Anne-Gaelle Planson
Author Mahel Zeghouf
Author Jacqueline Cherfils
Author Luc Malaval
Author Anne Blangy
Abstract Osteoporosis is caused by excessive activity of bone-degrading osteoclasts over bone-forming osteoblast. Standard antiosteolytic treatments inhibit bone resorption by inducing osteoclast loss, with the adverse effect of hindering also bone formation. Formation of the osteoclast sealing zone requires Dock5, a guanine nucleotide exchange factor for the small GTPase Rac, and C21, a chemical inhibitor of Dock5, decreases bone resorption by cultured osteoclasts. Here we show that C21 directly inhibits the exchange activity of Dock5 and disrupts osteoclast podosome organization. Remarkably, C21 administration protects mice against bone degradation in models recapitulating major osteolytic diseases: menopause, rheumatoid arthritis and bone metastasis. Furthermore, C21 administration does not affect bone formation and is not toxic. Our results validate the pharmacological inhibition of Dock5 as a novel therapeutic route for fighting osteolytic diseases while preserving bone formation.
Publication Nature Communications
Volume 6
Pages 6218
Date Feb 03, 2015
Journal Abbr Nat Commun
Language eng
DOI 10.1038/ncomms7218
ISSN 2041-1723
Library Catalog PubMed
Extra PMID: 25645278
Tags Animals, Arthritis, Female, Guanine Nucleotide Exchange Factors, Male, Mice, Mice, Inbred C57BL, original, Osteoclasts, Osteogenesis, Osteolysis, Sulfonamides
Date Added 2019/06/04 - 17:00:24
Date Modified 2019/06/05 - 11:03:43


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés